Cytek Biosciences (CTKB) Return on Capital Employed (2021 - 2026)

Cytek Biosciences' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 11.72% for Q1 2026.

• Quarterly Return on Capital Employed fell 587.0% year-over-year to 11.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.72% (down 587.0% YoY) and the FY2025 annual result came in at 10.03%, down 525.0% from the prior year.
• Return on Capital Employed was 11.72% for Q1 2026 at Cytek Biosciences, down from 10.09% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 1.31% in Q1 2022 and bottomed at 11.72% in Q1 2026.
• A 5-year average of 4.82% and a median of 5.85% in 2025 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2024 — Return on Capital Employed surged 138 bps — and 2026, when it tumbled 587 bps.
• Cytek Biosciences' Return on Capital Employed stood at 0.39% in 2022, then sank by 1477 bps to 6.18% in 2023, then advanced by 22 bps to 4.8% in 2024, then slumped by 110 bps to 10.09% in 2025, then fell by 16 bps to 11.72% in 2026.
• Business Quant data shows CTKB's Return on Capital Employed at 11.72% in Q1 2026, 10.09% in Q4 2025, and 7.59% in Q3 2025.